| 背景 | This product is a research-grade biosimilar of casdozokitug (development code SRF388), supplied as an unconjugated, non-therapeutic analog for research use only. It is built around the same target as the originator molecule, human interleukin-27 (IL-27), and is provided as a human IgG1, kappa immunoglobulin. Casdozokitug is a first-in-class antibody directed against IL-27, an immunoregulatory cytokine implicated in dampening antitumor immune responses; the originator has been evaluated clinically as monotherapy and in combination with checkpoint and anti-angiogenic agents in solid tumors such as non-small cell lung cancer and hepatocellular carcinoma. This reagent is intended to reproduce the target-binding behavior of that molecule for laboratory investigation rather than for any clinical or diagnostic application. It is manufactured to in-vivo research standards with low endotoxin content and is available in bulk milligram-to-gram quantities, making it suitable as a reference standard, binding control, or tool antibody in IL-27-focused studies. It is not a clinical drug product and carries no clone designation.
Interleukin-27 (IL-27) is a heterodimeric member of the IL-12 cytokine family, composed of the p28 subunit (encoded by IL27; UniProt Q8NEV9, also called IL-30) paired with EBI3. It signals through a receptor complex of IL-27Ralpha (WSX-1) and gp130, activating JAK/STAT (notably STAT1 and STAT3) and p38 MAPK pathways. IL-27 is produced largely by antigen-presenting cells and exerts context-dependent, often immunoregulatory effects on T cells, NK cells, macrophages, and B cells. In the tumor microenvironment it is associated with suppression of antitumor immunity and with induction of inhibitory checkpoint molecules, which is the rationale for therapeutically neutralizing it. Antibodies such as the casdozokitug originator engage IL-27 at an epitope overlapping the IL-27Ralpha interaction site, blocking receptor engagement and downstream signaling. |
|---|
